首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

亚太地区抗体药物偶联物市场预测至 2030 年 - 区域分析 - 按技术、应用和配销通路

市场调查报告书

商品编码

1481966

亚太地区抗体药物偶联物市场预测至 2030 年 - 区域分析 - 按技术、应用和配销通路

Asia Pacific Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology, Application, and Distribution Channel

出版日期: 2024年03月04日 | 出版商:

The Insight Partners | 英文 101 Pages | 订单完成后即时交付

价格

简介目录图表

2022年亚太地区抗体药物偶联物市值为15.3283亿美元，预计2030年将达到69.7103亿美元；预计2022年至2030年复合年增长率为20.8%。

同意管理中对人工智慧的需求不断增长，推动了亚太抗体药物偶联物市场的发展

癌症发生率上升主要导致对创新癌症治疗的需求不断增加。根据全球癌症观察站 (GLOBOCAN) 2020 年发布的估计，全球有 1,930 万癌症病例。中国和印度是癌症病例最多的国家之一。 GLOBOCAN 也估计，到 2040 年，印度的癌症病例将达到约 208 万，比 2020 年增长 57.5% 。死于癌症。最常见的癌症类型是肺癌、乳癌、结肠癌和直肠癌、摄护腺癌和乳癌。癌症发生率的上升引起了全世界的关注。以下是 2020 年全球报告的常见癌症病例清单。

表 1. 2020 年全球新癌症病例

序号癌症类型病例数（百万）

1胃1.09

2 皮肤（非黑色素瘤）1.2

3 前列腺 1.41

4 结肠和直肠 1.93

5 肺 2.21

6 乳房 2.26

癌症现在是一种生活方式疾病，常见于饮食习惯不健康和缺乏运动的人。此外，饮酒和吸烟也会增加罹癌的风险。低收入和中等收入国家的慢性传染病可进一步加剧癌症危险因子。根据世界卫生组织2022年2月发布的资料，2018年诊断的人中近18％患有人类乳突病毒（HPV）、幽门螺旋桿菌、B型肝炎病毒、丙型肝炎病毒和EB病毒等慢性传染病。

亚太地区抗体药物偶联物市场概况

亚太地区抗体药物偶联物（ADC）市场分为中国、日本、印度、韩国、澳洲和亚太其他地区。 ADC 市场的成长广泛受到公司合作、癌症发生率上升和临床试验增加的推动。

亚太国家参与开发ADC的龙头公司都有在研产品在完成临床试验后即将推向市场。 2023年6月，荣昌生物与信达生物签署协议，进入临床试验并提供达伯舒（信迪利单抗注射液）与新型间皮素（MSLN）标靶抗体药物偶联物（ADC）RC88的联合疗法，或称达伯舒 (TYVYT) 与 RC108，一种新型 c-Met 靶向 ADC。这些据称是治疗实体瘤的新疗法。根据协议，荣昌生物将对达伯舒进行1/2a期临床研究，以评估其抗肿瘤活性和安全性。该公司还有 Distamab vedotin (RC48) + PD1 组合正在研发中。此组合针对不同的癌症适应症分两个阶段进行评估，第一个组合处于III 期，评估用于治疗尿路上皮癌，第二个组合处于II 期，评估用于治疗肌肉浸润性膀胱癌和胃癌。

此外，日本公司正在推出突破性产品，预计将主导 ADC 市场。 2021 年 6 月，第一三共株式会社和阿斯特捷利康公司推出了 Enhertu，这是一类新型 ADC，专为治疗 HER2 低乳癌患者而开发。第一三共株式会社报告称，以美国和欧洲销售额计算，2023 年第一季销售额年增 156.6%。该公司销售额的如此巨大增长极大地促进了该国 ADC 市场规模的发展，预计未来几年将呈指数级增长。

亚太地区抗体药物偶联物市场收入及 2030 年预测（百万美元）

亚太地区抗体药物偶联物市场细分

亚太地区抗体药物偶联物市场根据技术、应用、配销通路和国家进行细分。

根据技术，亚太地区抗体药物偶联物市场抗体药物偶联物市场分为可裂解接头和不可裂解接头。 2022 年，可切割连接子部分占据了更大的份额。

根据应用，亚太地区抗体药物偶联物市场抗体药物偶联物市场分为血癌、乳癌、卵巢癌、尿路上皮癌等。 2022 年，乳癌细分市场所占比重最大。

根据配销通路，亚太地区抗体药物偶联物市场抗体药物偶联物市场分为医院药房、零售药房和线上药房。 2022年，医院药局部门占最大份额。

依国家/地区划分，亚太地区抗体药物偶联物市场分为澳洲、中国、印度、日本、韩国和亚太地区其他地区。 2022年，日本在亚太抗体药物偶联物市场占据主导地位。

辉瑞公司、罗氏公司、葛兰素史克公司、吉利德科学公司、阿斯特捷利康公司、安斯泰来製药公司、荣昌生物有限公司和武田製药有限公司是亚太地区抗体药物偶联物市场的一些领先公司。

Rising cancer incidences are primarily leading to the increasing demand for innovative cancer treatments. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the globe. China, and India were among the countries leading in cancer cases. The GLOBOCAN has also estimated that the cancer cases in India will be ~2.08 million by 2040, representing a rise of 57.5% from 2020. Similarly, as per the World Health Organization (WHO) data published in February 2022, ~10 million people have died from cancer. The most commonly seen cancer types were lung, breast, colon and rectum, prostate, and breast. The rising incidences of cancer have raised concerns worldwide. Below is the list of common cancer cases reported worldwide in 2020.

Table 1. New Cancer Cases Worldwide, in 2020

Sr. No. Cancer Type Number of Cases (Million)

1 Stomach 1.09

2 Skin (non-melanoma) 1.2

3 Prostate 1.41

4 Colon and Rectum 1.93

5 Lung 2.21

6 Breast 2.26

Cancer is now a lifestyle disease commonly seen among people with unhealthy food habits and who are physically inactive. Also, the consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. According to the WHO data published in February 2022, chronic infectious diseases such as human papillomavirus (HPV), Helicobacter pylori, hepatitis B virus, hepatitis C virus, and Epstein-Barr virus attributed to nearly 18% of the diagnosed in 2018. Also, promising results of ADCs are anticipated to accelerate their demand as an effective cancer treatment and propel the market growth.

Asia Pacific Antibody Drug Conjugates Market Overview

The Asia Pacific antibody drug conjugates (ADCs) market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the ADCs market is widely driven by company collaborations, growing incidences of cancer, and increasing clinical trials.

The leading companies in Asia Pacific countries that are involved in developing ADCs have pipeline products to be launched in the market after completing the clinical trials. In June 2023, RemeGen Co., Ltd. signed an agreement with Innovent Biologics, Inc. to enter clinical trials and supply combination therapies TYVYT (sintilimab injection) with RC88, a novel mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), or TYVYT with RC108, a novel c-Met-targeting ADC. These are claimed to be novel therapies to treat solid tumors. Under the agreement, RemeGen Co., Ltd will conduct Phase 1/2a clinical studies for TYVYT to evaluate the anti-tumor activity and safety. The company also has Distamab vedotin (RC48) +PD1 combination in the pipeline. The combination is evaluated in two phases for different cancer indications, first combination is in phase III, evaluated to treat urothelial cancer in and second is in phase II, evaluated to treat muscle invasive bladder and gastric cancer.

In addition, Japanese companies are introducing breakthrough products that are expected to dominate the ADCs market. In June 2021, Daiichi Sankyo Company, Limited, and AstraZeneca plc launched Enhertu-a novel class of ADCs developed to treat HER2-low breast cancer patients. Daiichi Sankyo Company, Limited reported a year-on-year sales growth of 156.6% in the first quarter of 2023 by combining the US and European sales. Such a huge growth in the company's sales has significantly contributed to the ADCs market size in the country and is estimated to grow exponentially in the coming years.

Asia Pacific Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Antibody Drug Conjugates Market Segmentation

The Asia Pacific antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.

Based on technology, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.

Based on application, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.

Based on distribution channel, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.

Based on country, the Asia Pacific antibody drug conjugates market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Japan dominated the Asia Pacific antibody drug conjugates market in 2022.

Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the Asia Pacific antibody drug conjugates market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Market Attractiveness

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Antibody Drug Conjugates Market - Key Industry Dynamics

4.1 Key Market Drivers:
- 4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
- 4.1.2 Rising Incidences of Cancer Cases
- 4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
- 4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
- 4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
- 4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:

5. Antibody Drug Conjugates Market - Asia Pacific Market Analysis

5.1 Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

6. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

6.1 Overview
6.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
- 6.3.1 Overview
- 6.3.2 Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
- 6.4.1 Overview
- 6.4.2 Non-cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

7.1 Overview
7.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
- 7.3.1 Overview
- 7.3.2 Blood Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
- 7.4.1 Overview
- 7.4.2 Breast Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
- 7.5.1 Overview
- 7.5.2 Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
- 7.6.1 Overview
- 7.6.2 Urothelial Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Antibody Drug Conjugates Market - Country Analysis

9.1 Asia Pacific Antibody Drug Conjugates Market, Revenue and Forecast To 2030
- 9.1.1 Overview
- 9.1.2 Asia Pacific Antibody Drug Conjugates Market Breakdown, by key Country - Revenue (2022) (US$ Million)
- 9.1.3 Asia Pacific: Antibody Drug Conjugates Market, by Country
  - 9.1.3.1 China
    - 9.1.3.1.1 Overview
    - 9.1.3.1.2 China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.1.3 China: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.1.4 China: Antibody Drug Conjugates Market, by Application
    - 9.1.3.1.5 China: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.2 Japan
    - 9.1.3.2.1 Overview
    - 9.1.3.2.2 Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.2.3 Japan: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.2.4 Japan: Antibody Drug Conjugates Market, by Application
    - 9.1.3.2.5 Japan: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.3 India
    - 9.1.3.3.1 Overview
    - 9.1.3.3.2 India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.3.3 India: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.3.4 India: Antibody Drug Conjugates Market, by Application
    - 9.1.3.3.5 India: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.4 South Korea
    - 9.1.3.4.1 Overview
    - 9.1.3.4.2 South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.4.3 South Korea: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.4.4 South Korea: Antibody Drug Conjugates Market, by Application
    - 9.1.3.4.5 South Korea: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.5 Australia
    - 9.1.3.5.1 Overview
    - 9.1.3.5.2 Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.5.3 Australia: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.5.4 Australia: Antibody Drug Conjugates Market, by Application
    - 9.1.3.5.5 Australia: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.6 Rest of Asia Pacific
    - 9.1.3.6.1 Overview
    - 9.1.3.6.2 Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.6.3 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.6.4 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Application
    - 9.1.3.6.5 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel

10. Asia Pacific Antibody Drug Conjugates Market-Industry Landscape

10.1 Overview
10.2 Organic Growth Strategies
- 10.2.1 Overview
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Companies' Manufacturing Capacities and Capabilities

11. Company Profiles

11.1 Pfizer Inc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Hoffmann-La Roche Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 GSK Plc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Gilead Sciences Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 AstraZeneca Plc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Astellas Pharma Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 RemeGen Co Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Takeda Pharmaceutical Co Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Asia Pacific Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 5. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 6. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 7. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 8. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 9. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 10. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 11. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 12. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 13. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 14. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 15. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 16. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 17. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 18. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 19. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 20. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 21. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 22. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 23. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 24. Glossary of Terms, Antibody Drug Conjugates Market

List Of Figures

Figure 1. Asia Pacific Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. Asia Pacific Antibody Drug Conjugates Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
Figure 6. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)
Figure 20. Asia Pacific: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 21. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)